Coherus Oncology, Inc. - Common Stock (NQ:CHRS)

1.160 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Coherus Oncology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Coherus to Report First Quarter 2024 Financial Results on May 9, 2024

May 01, 2024

From Coherus BioSciences, Inc.

Via GlobeNewswire

Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

April 24, 2024

From Coherus BioSciences, Inc.

Via GlobeNewswire

Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting

April 08, 2024

From Coherus BioSciences, Inc.

Via GlobeNewswire

Recap: Coherus BioSciences Q4 Earnings ↗

March 13, 2024

Via Benzinga

Earnings Preview For Coherus BioSciences ↗

March 12, 2024

Via Benzinga

Why Coherus Biosciences Stock Tumbled on Thursday ↗

March 14, 2024

The company fell well short of expectations for its fourth quarter.

Via The Motley Fool

Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update

March 13, 2024

From Coherus BioSciences, Inc.

Via GlobeNewswire

Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024

March 05, 2024

From Coherus BioSciences, Inc.

Via GlobeNewswire

Coherus Completes Divestiture of Ophthalmology Franchise

March 04, 2024

From Coherus BioSciences, Inc.

Via GlobeNewswire

Earnings Scheduled For March 13, 2024 ↗

March 13, 2024

Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million.

Via Benzinga

Coherus BioSciences Announces New Employment Inducement Grants

February 23, 2024

From Coherus BioSciences, Inc.

Via GlobeNewswire

Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

February 21, 2024

From Coherus BioSciences, Inc.

Via GlobeNewswire

Why Coherus BioSciences Stock Jumped Today ↗

February 06, 2024

As promised, Coherus is using the proceeds of a recent divestiture to pay down debt and reduce interest expenses.

Via The Motley Fool

Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP

February 05, 2024

From Coherus BioSciences, Inc.

Via GlobeNewswire

Why Coherus BioSciences Stock Is Sinking Today ↗

January 23, 2024

The positive reaction to Coherus' sale of its ophthalmology franchise to Sandoz didn't last long.

Via The Motley Fool

Why Coherus Biosciences Popped Today ↗

January 22, 2024

Coherus is divesting its non-core ophthalmology franchise.

Via The Motley Fool

Why CommScope Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

January 22, 2024

Shares of CommScope Holding Company, Inc. (NASDAQ: COMM) fell sharply during Monday’s session. B of A Securities analyst Tal Liani downgraded CommScope from Neutral to Underperform and lowered the...

Via Benzinga

Why Is Cancer Immunotherapy Focused-Coherus BioSciences Stock Trading Higher Today? ↗

January 22, 2024

Coherus BioSciences agreed to sell its ophthalmology franchise for $170M to Sandoz. This aligns with CHRS' focus on oncology and will help reduce debt and overhead costs.

Via Benzinga

Why Is Cartesian Therapeutics (RNAC) Stock Down 5% Today? ↗

January 22, 2024

Cartesian Therapeutics stock is falling on Monday as investors react to a delisting notice for RNAC shares due to its low trading price.

Via InvestorPlace

Why Is B. Riley Financial (RILY) Stock Down 11% Today? ↗

January 22, 2024

B. Riley Financial stock is falling on Monday as RILY investors react to reports of an SEC probe and the company's stance on the news.

Via InvestorPlace

Topics Regulatory Compliance

Why Is Coherus BioSciences (CHRS) Stock Up 17% Today? ↗

January 22, 2024

Coherus BioSciences stock is rising on Monday as CHRS investors react to a $170 million divestment of its CIMERLI ophthalmology franchise.

Via InvestorPlace

Why Coherus BioSciences Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket ↗

January 22, 2024

Shares of Coherus BioSciences, Inc. (NASDAQ: CHRS) shares rose sharply in today’s pre-market trading after the company announced an agreement to divest ophthalmology franchise to Sandoz in $170 million...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

January 22, 2024

We're starting the trading week with a breakdown of the biggest pre-market stock movers worth knowing about on Monday!

Via InvestorPlace

Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal

January 22, 2024

From Coherus BioSciences, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

January 19, 2024

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

January 18, 2024

Via Benzinga

Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium

January 18, 2024

From Coherus BioSciences, Inc.

Via GlobeNewswire

Veradigm, Aehr Test Systems, Saratoga Investment And Other Big Stocks Moving Lower On Wednesday ↗

January 10, 2024

U.S. stocks traded slightly higher, with the Dow Jones index gaining over 20 points on Wednesday. Shares of Veradigm Inc. (NASDAQ: MDRX) shares fell sharply during Wednesday’s session.

Via Benzinga

Topics Stocks

Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 03, 2024

From Coherus BioSciences, Inc.

Via GlobeNewswire

Coherus Announces U.S. Launch of LOQTORZI™

January 02, 2024

From Coherus BioSciences, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.